Automated Author ProfileLee, Sangmi
Lee, Sangmi
Current S-Index
Sum of Dataset Indices for all datasets
Average Dataset Index per Dataset
Average Dataset Index per dataset
Total Datasets
Total datasets for this author
Average FAIR Score
Average FAIR Score per dataset
Total Citations
Total citations to the author's datasets
Total Mentions
Total mentions of the author's datasets
S-Index Interpretation
The S-Index (Sharing Index) is a comprehensive metric that represents the cumulative impact of all your datasets. It is calculated as the sum of Dataset Index scores across all your claimed datasets.
What it means:
- A higher S-index indicates greater overall impact of your datasets relative to typical datasets in their fields of research
- The S-Index grows as you add more datasets or as existing datasets gain more citations and mentions
- It provides a single number to track your research data impact over time
Current S-Index: 3.3 (sum of 4 datasets Dataset Index scores)
More information here.
S-Index Over Time
Cumulative Citations Over Time
Cumulative Mentions Over Time
Datasets
This study was conducted to explore the unmet needs and health-related quality of life (QOL) of family caregivers who support cancer patients, and to determine the impact of these unmet needs on their health-related QOL. A descriptive study was conducted from July 1 to July 30, 2023, in which a survey was administered to 129 family caregivers of cancer patients undergoing outpatient treatment at a general hospital of South Korea.
Authors
- Lee, Sangmi ;
- Kim, Juyeun
This study was conducted to explore the unmet needs and health-related quality of life (QOL) of family caregivers who support cancer patients, and to determine the impact of these unmet needs on their health-related QOL. A descriptive study was conducted from July 1 to July 30, 2023, in which a survey was administered to 129 family caregivers of cancer patients undergoing outpatient treatment at a general hospital of South Korea.
Authors
- Lee, Sangmi ;
- Kim, Juyeun
Pharmacokinetics & safety of CT-P17 (40 mg/0.4 mL) vs reference adalimumab: randomised study in healthy Japanese adults: supplementary methods
Authors
- Ogama, Yoichiro ;
- Lee, Sangmi ;
- Cha, JungBin ;
- Choi, Eunjin ;
- Jeon, DaBee ;
- Kim, Sunghyun ;
- Tanaka, Takanori ;
- Haranaka, Miwa ;
- Bae, YunJu
Pharmacokinetics & safety of CT-P17 (40 mg/0.4 mL) vs reference adalimumab: randomised study in healthy Japanese adults: supplementary methods
Authors
- Ogama, Yoichiro ;
- Lee, Sangmi ;
- Cha, JungBin ;
- Choi, Eunjin ;
- Jeon, DaBee ;
- Kim, Sunghyun ;
- Tanaka, Takanori ;
- Haranaka, Miwa ;
- Bae, YunJu